1 / 23

Giorgio F. Pacelli MD, Vito Belloli MD, UOC oculistica, Ospedale di Arona (No).

Rapid unusual reasorbtion of drusenoid subfoveal lesions in AMD and pseudovitelliform maculopathy documented with SD-OCT and autofluorescence. Giorgio F. Pacelli MD, Vito Belloli MD, UOC oculistica, Ospedale di Arona (No).

aderes
Télécharger la présentation

Giorgio F. Pacelli MD, Vito Belloli MD, UOC oculistica, Ospedale di Arona (No).

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rapid unusual reasorbtion of drusenoid subfoveal lesions in AMD and pseudovitelliform maculopathydocumented with SD-OCT and autofluorescence. Giorgio F. Pacelli MD, Vito Belloli MD, UOC oculistica, Ospedale di Arona (No).

  2. Case Report 1: BO 72 years old female February 2009:daily intake of an AREDS2 formulation containing microalgale DHA e tocotrienols Visus 0,9 0,1 logmar Visus 10/10 0,0 logmar 8 months’ follow-up 20 months’ follow-up

  3. 8 months’ follow-up Autofluorescence evolution. Baseline 1 & ½ year follow-up

  4. BO: Fellow eye evolution. ETDRS BCVA 0.0 logm 8 months’ evolution ETDRS BCVA 0.0 logm 20 months’evolution

  5. 8 months’ follow-up Autofluorescence evolution Baseline 20 months’ evolution

  6. Case report 2 (MC): 75 years old famaleareds 4 category AMD left eyedaily intake of an AREDS2 formulation containing microalgale DHA e tocotrienols BCVA: 0.8 dec 0.16 logm 18 Months later 8 months later BCVA 1.0 dec 0.0 logm

  7. 8 months later baseline AF evolution: 18 months later

  8. (MC)_ SD-OCT Cirrus Zeiss Follow up ( RPElevel scan slice )

  9. Case report 3: (BD): 80 years old male may 2009: daily intake of an AREDS2 formulation containing microalgale DHA e tocotrienols BCVA 0.6 dec; 0.24 logmar +1 .75 sf Case report 3(BD): 04-10 ( 12 months’ follow up) BCVA 0.9 dec; 0.04 logmar +0.75 sf

  10. BD: Right eye of the same patients: BCVA 1.0 BCVA 1.0 12 months later

  11. Case report 4 RA: AMD with RPE pattern shape abnormalities and metamorphopsia complaint in the latest 2 months: (AREDS 4 category: controlateral eyes evoluted AMD):

  12. BCVA 0.5 dec; 0,3 logmar Case report 4: areds 2 formulation prescription 8 months later: 0.9 dec: 0.04 logm 3 montths later: BCVA 0.8 dec)

  13. Case report 6 (BI): baseline oct 08: BCVA 0.9 dec; 0.06 logmar extrafoveal CNV treated directly with argon laser in a patients supplemented with AREDS1 formulation 3 mos later: BCVA 0.9 dec ( 0.1 log); Increment in soft drusen confluence; no more evidence of CNV

  14. 05-10 BCVA 0.9 0.1 logm 20 months later after a daily intake of an AREDS2 formulation containing ω3-microalgale & tocotrienols 08-2010 BCVA 0.9 0.04 logm

  15. Case report 7: Pseudovitelliform macular lesion with a subfoveal lipofusinic accumulation (BS). Daily intake of AREDS2 (tocotrienols e microalgale ω3 ): BCVA 0.8 dec ( 0.1 logmar) 6 months later: BCVA 0.9 ( 0,08 logmar)

  16. BS: 15 months later: further reduction of lipofuscine.

  17. Case report 7: Left eye: PV maculopathy & foveal PRC misalignement BCVA 0.8 (0.1 logmar) 6 months later: BCVA 0.9 ( 0.02 logmar)

  18. 15 months later: regularization of PRC disalignament

  19. PV maculopathy treated with an areds1 formulation: BCVA 0.8 ( 0.1 logmar) ILM- EPR Line

  20. 1 year follow up (ω3 free formulation): BCVA 0.1 dec 1.0 logmar (!!!!) Linea ILM EPR post Linea ILM- EPR pre

  21. Take home message: • The evidence of SD OCT and AF evolution of these drusenoid lesions suggest the utility of AREDS-2 formulation in preventing AMD evolution, waiting for confirmatory results coming out from ongoing AREDS2 studies. Thank you for your attention

More Related